Highlights GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Delayed Nasdaq Other stock markets 11:51:40 2024-05-15 am EDT			5-day change	1st Jan Change
3.02 ^USD	-5.43%		-2.58%	-60.52%

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	Nov. 06	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
GT Biopharma Taps Cytovance Biologics as Manufacturing Partner for Leukemia Drug	22-08-31	MT
Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650	22-08-30	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
GT Biopharma Announces TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data	22-03-21	CI
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021	21-12-08	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021	21-09-15	CI
GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies	21-09-13	CI
GT Biopharma : Gets Two New Patents Covering Natural Killer Cell Engager Platform	21-09-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Highlights

Filters